Company intelligence / Profile preview

Phase Holographic Imaging

Lund, Sweden

Ownership: Private
Development stage: Commercial

Overview

PHI develops non-invasive live cell imaging systems using QPI technology, enabling real-time analysis of cell cultures without harming cells. The company is expanding into regenerative medicine and clinical applications.

Therapeutic areas: OtherOncologyHematology
Modalities: Device
Industry: Pathology

Partnerships

Bayer AGNational Institutes of HealthHarvard UniversityStanford UniversityNovo Nordisk A/S

Beyond the preview

Go deeper on Phase Holographic Imaging.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phase Holographic Imaging.

Explore the full profile